Peritoneal Neoplasms

• 

  Subject Areas on Research

  • 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. 
  • A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype. 
  • A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. 
  • A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. 
  • A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. 
  • A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. 
  • A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. 
  • A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. 
  • A unique case of rhabdoid tumor presenting as hemoperitoneum in an infant. 
  • Abdominal leiomyosarcoma: aggressive management. 
  • Abdominal pain and a pelvic mass. 
  • Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. 
  • Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience. 
  • Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. 
  • Asbestos Fiber Concentrations in the Lungs of Brake Repair Workers: An Updated Analysis Using Several Regression Methods to Handle Nondetectable Measurements. 
  • Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases. 
  • Autocrine growth stimulation by transforming growth factor alpha in asbestos-transformed rat mesothelial cells. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. 
  • Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. 
  • Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. 
  • Colonic uptake of Tc-99m MDP in pseudomembranous colitis. 
  • Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. 
  • Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. 
  • Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries. 
  • Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. 
  • Crocidolite and mesothelioma. 
  • Current status and future directions in appendiceal cancer with peritoneal dissemination. 
  • Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. 
  • Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis. 
  • Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. 
  • Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: non-colorectal indications. 
  • Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer. 
  • Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. 
  • Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor. 
  • Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. 
  • Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. 
  • Desmoplastic small round cell tumor masquerading as advanced ovarian cancer. 
  • Diagnosis of posttransplant granulocytic sarcoma by fine-needle aspiration cytology and flow cytometry. 
  • Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. 
  • Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. 
  • Epidemiology of asbestos-related diseases. 
  • Exposure to brake dust and malignant mesothelioma: a study of 10 cases with mineral fiber analyses. 
  • Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. 
  • Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 
  • Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. 
  • Genitourinary resection at the time of cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis is not associated with increased morbidity or worsened oncologic outcomes: a case-matched study. 
  • Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. 
  • Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. 
  • Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. 
  • Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial. 
  • Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. 
  • Identical-twin small-bowel transplant for desmoid tumour. 
  • Imaging of pediatric mesenteric abnormalities. 
  • Immature omental teratoma. 
  • Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor. 
  • Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 
  • Implications of peritoneal cytology for pancreatic cancer management. 
  • In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. 
  • Intraductal papillary mucinous neoplasm (IPMN) with extra-pancreatic mucin: a case series and review of the literature. 
  • Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. 
  • Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. 
  • Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. 
  • Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. 
  • Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. 
  • Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. 
  • Is Intraperitoneal Chemotherapy Dead? 
  • Is port site resection necessary in the surgical management of gallbladder cancer? 
  • Laparoscopy and mesothelioma. 
  • Large mesenteric lymphangioma in an adult patient: an unusual presentation of a rare disease. 
  • Localized malignant mesothelioma. 
  • Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. 
  • Malignant Mesothelioma and Its Non-Asbestos Causes. 
  • Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. 
  • Malignant mesothelioma in women. 
  • Malignant mesothelioma not related to asbestos exposure: Analytical scanning electron microscopic analysis of 83 cases and comparison with 442 asbestos-related cases. 
  • Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. 
  • Malignant peritoneal mesothelioma and Crohn disease. 
  • Malignant peritoneal mesothelioma in patients with endometriosis. 
  • Management of peritoneal carcinomatosis from colorectal cancer. 
  • Mesotheliomas induced in rats by the fibrous mineral erionite are independent from p53 alterations. 
  • Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms. 
  • Metastatic melanoma of gastrocolic ligament treated with minimally invasive approach. 
  • Mineral fiber content of lung tissue in patients with environmental exposures: household contacts vs. building occupants. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma. 
  • Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. 
  • Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. 
  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. 
  • Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors. 
  • Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. 
  • Omental cakes in American Burkitt lymphoma. Computed tomography demonstration. 
  • Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. 
  • Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. 
  • Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. 
  • Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. 
  • Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. 
  • Ovarian teratoma with glial implants on the peritoneum. An analysis of 12 cases. 
  • Pathology of human mesothelioma. Etiologic and diagnostic considerations. 
  • Patient rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC). 
  • Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. 
  • Pediatric radiology case of the day. Peritoneal carcinomatosis. 
  • Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. 
  • Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases. 
  • Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 
  • Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. 
  • Peritoneal carcinomatosis: preoperative CT with intraperitoneal contrast material. 
  • Peritoneal fluid prolactin in infertile women with endometriosis: lack of evidence of secretory activity by endometrial implants. 
  • Peritoneal lymphomatosis. 
  • Peritoneal metastases in two patients with pineoblastoma and ventriculo-peritoneal shunts. 
  • Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. 
  • Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. 
  • Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 
  • Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. 
  • Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. 
  • Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. 
  • Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy. 
  • Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. 
  • Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. 
  • Primary peritoneal and ovarian cancers: an epidemiological comparative analysis. 
  • Progesterone receptor activity in leiomyomatosis peritonealis disseminata. 
  • Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection. 
  • Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. 
  • Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases. 
  • Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC. 
  • Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. 
  • Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. 
  • Rapid photothermal intracellular drug delivery using multiwalled carbon nanotubes. 
  • Reduction of the intraperitoneal inflammation associated with endometriosis by treatment with medroxyprogesterone acetate. 
  • Risk of occult irresectable disease at liver resection for hepatic colorectal cancer metastases: a contemporary analysis. 
  • Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. 
  • Routine Admission to Intensive Care Unit After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy: Not Always a Requirement. 
  • Rt-PCR increases detection of submicroscopic peritoneal metastases in gastric cancer and has prognostic significance. 
  • Sarcomatoid Peritoneal Mesothelioma: Clinicopathologic Correlation of 13 Cases. 
  • Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. 
  • Screening for familial ovarian cancer: a ray of hope and a light to steer by. 
  • Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? 
  • Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. 
  • Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 
  • Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. 
  • Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 
  • Stoma Creation and Reversal After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. 
  • Surgical options for advanced/metastatic gastrointestinal stromal tumors. 
  • Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? 
  • Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. 
  • Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. 
  • Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. 
  • The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. 
  • The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. 
  • The current role of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of appendiceal tumors. 
  • The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. 
  • The natural history of colorectal carcinoma in adolescents. 
  • The role of analytical SEM in the determination of causation in malignant mesothelioma. 
  • The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer with peritoneal surface disease. 
  • The separation of benign and malignant mesothelial proliferations. 
  • The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. 
  • Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer. 
  • Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. 
  • Translation considerations for hyperthermic intraperitoneal chemotherapy. 
  • Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. 
  • Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. 
  • Twenty-five years of fiber analysis: what have we learned? 
  • Use of FDG-PET imaging for patients with disseminated cancer of the appendix. 
  • Usefulness of sonographic guidance during percutaneous biopsy of mesenteric masses. 
  • Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. 
  • Well-differentiated papillary mesothelioma. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Dement, John McCray, Professor Emeritus in Family Medicine and Community Health, Family Medicine & Community Health,Occupational & Environmental Medicine
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Moorman, Patricia Gripka, Professor in Family Medicine and Community Health, Duke Cancer Institute
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology